Kedrion supports Fondazione Paracelso’s activities in Afghanistan
Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries
Kedrion Notes 2019 Tender Offer results
Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000
Cash Tender Offer for Notes due 24 April 2019
Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019
KEDPlasma welcomes donors to its new Augsburg collection center
Plasma collected in Germany is essential to Kedrion Biopharma’s plasma-derived therapies
Revolutionary PID testing from Tuscany, Italy
Kedrion at Meyer Hospital’s side to promote early diagnosis of primary immunodeficiencies
Humanitarian programme to reduce the gap in the access to clotting factors
Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London
Kedrion Continues Global Expansion with Dedication Ceremony at US Facility
Biopharma Company Celebrates with Local Guests and Dignitaries in Melville, New York
Kedrion SpA’s Shareholders approve 2014 financial statement
A 466 million euros’ turnover with a 9,8% rise on 2013
Kedrion supported the XI World Hemophilia Day
An increasingly tailor-made prophylaxis lets sports and hemorrhagic conditions live together
I triumphed in my race for life!
I was about six months old when I was diagnosed with severe hemophilia A.At the time, each hemorrhage required hospitalization. Sadly, by the time I was treated, the affected joints had been invaded by blood and were unbearably painful. It was a difficult childhood, but I did not give up, and from my adolescence on